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ABSTRACT
Introduction: Strong centrally acting
analgesics, including tapentadol prolonged
release (PR), have demonstrated efficacy for
the management of non-malignant, chronic
pain. Maintaining patient independence,
including the ability to drive safely, is a key
goal of long-term analgesic therapy. This
multicenter, open-label, phase 3b trial
evaluated the effects of tapentadol PR on
driving ability.
Methods: This study included patients who had
completed previous tapentadol PR trials for
severe low back or osteoarthritis pain. After at
least 6 weeks of dose stability, patients
continued taking tapentadol PR (50–250 mg
twice daily) and could take supplemental
immediate-release tapentadol 50 mg, except
on the day before or day of the driving test
(before the test). Pain intensity was assessed
using an 11-point numerical rating scale. The
Vienna Test System-Traffic Plus was used to
assess cognitive and psychomotor function. The
key surrogate parameter for driving ability was a
global judgment based on 6 battery tests.
Results: Thirty-eight patients enrolled and
completed the trial, and 35 patients completed
all 6 tests. Pain scores remained unchanged
from enrollment to final visit [mean (standard
deviation) change, –0.2 (1.0)]. Approximately
two-thirds [65.7% (23/35)] of patients were
classified as fit to drive based on the global
judgment of driving-specific ability [34.3% (12/
35) not fit to drive]. Total daily tapentadol PR
dose ([200 vs. B200 mg/day) did not affect
global judgment of driving ability (P = 0.4885).
Two adverse events (considered unrelated to
study drug) were reported.
Conclusion: Results suggest that most patients
receiving a stable dose of tapentadol PR for
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severe, chronic pain would be able to drive,
consistent with earlier studies evaluating stable
treatment with strong opioids. Study design
limitations and needs for individual patient
assessment must be considered in clinical
practice.
Keywords: Chronic pain; Driving ability;
Opioids; Pain; Tapentadol prolonged release
INTRODUCTION
Strong centrally acting analgesics (e.g., opioids)
are gaining acceptance for use in the
management of non-malignant, chronic pain
[1–3]. In addition to relieving pain, goals of
long-term analgesic therapy are to allow patients
to maintain their independence and stay active
[4]. The ability to drive safely is a key component
of daily living [4]. Studies have shown that
patients on stable doses of opioid analgesics
may be able to drive safely based on individual
evaluations [5–10]. However, medications with l-
opioid receptor agonist activity may adversely
affect patients’ cognitive and psychomotor
performance, particularly during titration when
dose changes occur [11–15].
Tapentadol is a centrally acting analgesic
with two mechanisms of action, l-opioid
receptor agonism and noradrenaline reuptake
inhibition [16, 17]. Tapentadol prolonged
release (PR) is approved in Europe for the
management of severe chronic pain in adults,
which can be adequately managed only with
opioid analgesics [18], and in the United States
(tapentadol extended release) for the
management of moderate to severe, chronic
pain, and neuropathic pain associated with
diabetic peripheral neuropathy in adults when
a continuous, around-the-clock opioid
analgesic is needed for an extended period of
time [19]. In a randomized, controlled phase 3
study [20], tapentadol PR (100–250 mg twice
daily [bid]) was associated with a lower
incidence of dizziness and fewer
discontinuations due to nervous system side
effects than oxycodone controlled release
(20–50 mg bid). The lower incidence of
nervous system side effects with tapentadol
compared with oxycodone may be related to
the contribution of noradrenaline reuptake
inhibition to its analgesic activity [17, 20].
This multicenter, open-label, phase 3b trial
(EudraCT: 2009-015397-35) evaluated cognitive
and psychomotor performance as measured by
a validated methodology [21] (Vienna Test
System-Traffic Plus; Schuhfried GmbH,
Mo¨dling, Austria) based on a global judgment
as the key outcome surrogate parameter for
driving ability in patients with severe, chronic
low back pain or osteoarthritis knee pain on
stable treatment with tapentadol PR. Based on
prior results showing that patients on stable
doses of opioid analgesics may be able to drive
safely (depending on individual results) [5–10],
we hypothesize that many patients receiving
stable doses of tapentadol PR for severe, chronic
pain will be considered fit to drive.
METHODS
This study was conducted between February 26,
2010 and September 3, 2010. Seven sites in
Germany contributed patients for participation.
Each site received approval of the study
protocol from an Independent Ethics
Committee. The test site (where the Vienna
Test System-Traffic Plus was conducted) was the
Comprehensive Pain Center at Carl Gustav
Carus University Hospital of Dresden. All
patients provided written informed consent
before the start of any trial activity.
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PATIENT POPULATION
This study included men and women
18–70 years of age who had completed a
previous clinical trial of tapentadol PR for the
management of chronic low back or
osteoarthritis pain [22, 23]. Patients were
required to be fluent in German (based on the
investigator’s assessment) and taking an
individually titrated (balancing efficacy and
tolerability) dose of tapentadol PR (50–250 mg
bid) that had been stable for C2 weeks.
Patients with physical, neurological, or
psychological disabilities, or symptoms that
would interfere with the study assessment were
excluded from the study. Women were excluded
if they were pregnant or breastfeeding. Patients
were also excluded if they had a history of allergy,
hypersensitivity, or contraindications to
tapentadol or its excipients, including acute or
severe bronchial asthma or hypercapnia, or
known or suspected paralytic ileus. Additional
exclusion criteria included a known or suspected
history of alcohol or drug abuse; a positive urine
drug screen (except for opioids); severe renal
impairment; moderately or severely impaired
hepatic function; a history of seizure disorder or
epilepsy; mild/moderate traumatic brain injury,
stroke, transient ischemic attack, or brain
neoplasm within the past year; or severe
traumatic brain injury within the last 15 years.
The use of monoamine oxidase inhibitors
was prohibited during the study; the use of
alcohol on the day before the test visit and prior
to completion of the Vienna Test System-Traffic
Plus and the use of antihistamines on a regular
basis were also prohibited. The following
medications were prohibited for 14 days prior
to enrollment and during the study if they had
been verified to cause central nervous system
side effects in an individual patient (based on
information from the originating trial):
anticholinergics, anticonvulsants, atypical
antidepressants, selective serotonin reuptake
inhibitors, tetracyclic and tricyclic
antidepressants, antiemetics, antitussives,
systemic bronchodilators, dopaminergic drugs,
and neuroleptics; if the medication had been
taken on a regular basis at a stable dose for at
least 14 days prior to enrollment and had not
caused central nervous system side effects, the
patient could continue taking it.
STUDY DESIGN
This multicenter, open-label, phase 3b trial
included 3 periods: an enrollment period, a
preparation and testing period, and a
finalization period. The enrollment period
(Day 1) coincided with the final visit of the
previous trial [22, 23] or occurred within 12 h of
the last intake of tapentadol PR in that trial.
Upon enrollment, patients received a 30-day
supply of tapentadol PR at their current dose,
which was sufficient to cover treatment for the
maximum period between enrollment and the
final visit. Patients also received a 30-day supply
of tapentadol immediate release (IR) 50 mg,
which could be taken on demand (B2 doses/
day, C4 h apart; total tapentadol dose B500 mg/
day). No additional analgesic medication was
allowed during the study.
During the preparation and testing period
(between Day 2 and 21), patients continued to
take tapentadol PR (50–250 mg bid). On the day
of the test, a physical examination was
performed, vital signs were measured, and a
urine screening and an alcohol breath test were
performed. Patients were then trained on the
driving test system, and the test was
administered. No tapentadol IR or alcohol
consumption was allowed on the day before or
the day of the driving test until after the test
was completed.
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The finalization period (between Day 3 and
30) lasted from the day after the test until the
final study visit. The final study visit could
occur at any time after the test visit (e.g., if the
test visit occurred on Day 2, the final visit could
occur on Day 3). During the finalization period,
patients continued to take tapentadol PR
(50–250 mg bid) to ensure a stable dose
regimen. All unused study drug was collected
and all drug was accounted for at the final visit.
STUDY EVALUATIONS
Cognitive and psychomotor function was
assessed using the Vienna Test System-Traffic
Plus as a surrogate for evaluating driving ability
under stable treatment conditions; the overall
test system consists of ten single tests. The
Vienna Test System-Traffic Plus is a validated
electronic test battery [21], consisting of
individual tests produced in up to 27
languages [24]. The test system includes a
color monitor (and/or projector), speakers, a
special keyboard with joysticks, steering wheels,
two pedals, two peripheral displays with a light
diode matrix, and the software. The test system
provides an empirically validated model (called
a ‘‘neuronal network’’), which uses test scores to
predict results of a standardized driving test.
The model enables subjects to be assigned to an
overall classification of driving-specific ability
(specified as the global judgment of driving
ability) based on the following six battery tests:
the adaptive matrices test, the cognitrone,
the tachistoskopic traffic conception test, the
reaction test, the determination test, and the
peripheral perception test. The global judgment
of driving ability was used to determine
whether a subject’s psychomotor performance
and cognition fulfill the criteria of driving a car
safely. A binary (yes/no classification) outcome
was created for each of the individual
performance tests, with a successful outcome
(i.e., positive response) defined as a score that
was C16th percentile on the respective test
(based on a normal distribution in healthy
subjects) [10]. For the global judgment of
driving ability, subjects who were considered
fit to drive fell into one of the following three
subgroups: subjects with adequate driving-
related ability (score C16th percentile on all 6
battery tests), subjects with adequate driving
ability and performance deficits that could be
compensated (score \16th percentile on C1 of
the battery tests, but performance in other areas
is sufficient to compensate for performance
deficits), or subjects with performance deficits
that could be compensated to a limited extent
(score \16th percentile on C1 of the battery
tests, and test results do not conclusively
demonstrate that subject’s performance in
other areas is sufficient to compensate for
performance deficits). Subjects with
performance deficits that could be
compensated to a limited extent were only
considered fit to drive if the scores obtained for
the cognitrone, determination test, and
tachistoskopic traffic conception tests were
C16th percentile. Subjects who were
considered not fit to drive fell into 1 of the
following subgroups: subjects with performance
deficits that could be compensated to a limited
extent with a score \16th percentile on C1 of
the cognitrone, determination test, or
tachistoskopic traffic conception tests; non-
compensable performance deficits (score \16th
percentile on C1 of the battery tests, and
adequate performance in other areas was not
sufficient to compensate for performance
deficits); or inadequate driving-related ability
(score \16th percentile on the majority of
battery tests).
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The adaptive matrices test is a non-verbal test
that requires subjects to identify the figurative
pattern of a matrix and select the item from
eight possible answers that completes the
pattern; an estimate of general intelligence is
produced based on the Rasch model according to
the maximum likelihood method. The
cognitrone requires the subject to compare an
abstract figure with a model figure and
determine the correspondence between the
figures; the mean time to correct rejections is
used as a measure of selective attention. For the
tachistoskopic traffic perception test, subjects are
shown pictures of traffic scenes (1 s each) and
then asked to select items they recalled being in
each picture from a list of 5 items; the number of
lists answered correctly is used as a measure of
perceptual speed. The reaction test, which
measures decision speed and physical motor
speed, involves presenting subjects with visual
stimuli (colored circles) and auditory stimuli; the
subject signals when a yellow circle and specific
auditory signal appear in combination. The
subject is asked to ignore all other auditory and
visual signals; the mean reaction time serves as a
measure of decision speed. In the determination
test, subjects are required to identify various
stimuli and react to those stimuli by pressing a
corresponding response button on a panel (or
pedal); the stimuli are presented slightly faster
than would be optimal for the respondents’
individual reaction speed, resulting in a
condition of sensory stress. For this test, the
number of correct reactions is used to assess the
resilience of attention and reaction speed under
sensory stress. The peripheral perception test is
used to assess field of view and divided attention.
In this test, subjects are asked to press a foot
pedal when moving light stimuli (presented in
the periphery of the subject’s visual field) appear;
at the same time, the subject is required to track
a moving object and must therefore distribute
their attention between the two tasks. In
addition to these six battery tests, other
components of the Vienna Test System-Traffic
Plus that were evaluated included the Vienna
Risk Taking Test-Traffic (assesses performance in
a potentially dangerous traffic situation), the
two-hand coordination test (measures
sensorimotor coordination), the vigilance test
(assesses attention in the form of sustained
vigilance), and the visual pursuit test (assesses
visual orientation ability and skill in gaining an
overview).
Pain intensity was assessed on an 11-point
numerical rating scale-3 (NRS-3; recalled average
pain intensity score during the last 3 days from
0 = ‘‘no pain’’ to 10 = ‘‘pain as bad as you can
imagine’’) at the enrollment and final visits. At
the time of the test, patients also reported their
current pain intensity (11-point NRS).
Safety evaluations included treatment-
emergent adverse event (TEAE) reporting, vital
sign evaluations, physical examinations, and a
driving history questionnaire. All adverse events
that occurred between the enrollment and final
visits were defined as TEAEs. Vital signs,
including systolic and diastolic blood pressure,
pulse rate, and respiratory rate, were measured
at the enrollment, test, and final visits. For
patients with a valid driving license, the driving
history questionnaire assessed the year of
passing the driving test, class of driving
license, approximate distance driven in the
last year, and whether the patient felt fit to
drive.
STATISTICAL ANALYSES
Based on exploratory studies of the effects of
opioids on driving ability [9, 10], it was
estimated that 30 patients would be sufficient
to descriptively explore the effects of multiple
doses of tapentadol PR on cognitive and
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psychomotor performance as surrogate
parameters for driving ability.
Pharmacodynamic and efficacy-related
parameters were analyzed for all patients who
completed the six battery tests of the Vienna
Test System-Traffic Plus (the per protocol
population). Safety analyses were performed
for all patients who took C1 dose of
tapentadol PR or tapentadol IR (the safety
population). All statistical analyses were
performed using SAS Software (SAS Institute
Inc., Cary, NC, USA).
The global judgment (an outcome surrogate
parameter for driving ability) and outcomes for
the individual performance tests were
summarized descriptively using patient counts
and percentages. Pain intensity scores at the
enrollment, test, and final visits were
summarized using descriptive statistics. TEAEs
were summarized using the number and
percentage of patients with adverse events by
system organ class and preferred term.
Unlike comparable trials of strong opioids [9,
21, 25], this trial did not compare patients
receiving tapentadol with a group of historical
controls consisting of untreated healthy
subjects. The Vienna Test System-Traffic Plus
can use a reference population for internal
comparison; because the test system has been
validated against a standard driving test [21], no
comparative arm was required. Threshold
values for each test were defined as the 16th
percentile of normally distributed test data from
a representative age-independent sample that
was transformed into a standard normal
distribution.
Exploratory subgroup analyses were
conducted to determine the impact of
intelligence quotient (IQ; obtained from the
adaptive matrices test results), age, educational
level (captured as part of the Vienna Test
System-Traffic Plus), daily dose of tapentadol
PR, current pain intensity, and distance driven
in the previous year on global judgment.
RESULTS
Patients
The safety population included 38 patients who
were enrolled and completed the trial.
Demographic data for those patients are
summarized in Table 1. The per protocol
population (patients who completed all 6
battery tests of the Vienna Test System-Traffic
Plus) included 35 patients. Three patients in the
safety population were excluded from the per
protocol population because of major protocol
violations. One of those patients had a history
of alcohol abuse and impaired hepatic function
due to formal alcohol abuse, both of which
violated the study exclusion criteria. One
patient took a prohibited medication
(benzodiazepine), and one patient took
tapentadol IR on the day of the test visit.
In the safety population, 86.8% (33/38) of
patients held a valid driving license, and 78.9%
Table 1 Demographic characteristics (safety population)
Characteristic All patients (N5 38)
Age, years







Body mass index, kg/m2
Mean (SD) 32.0 (6.71)
SD standard deviation
22 Pain Ther (2014) 3:17–29
(30/38) considered themselves fit to drive. The
mean [standard deviation (SD)] estimated
distance that patients with a valid driving
license had driven in the previous year was
12,084.8 (12,203.8) km per patient.
Treatment Exposure
In the safety population, the mean (SD)
duration of tapentadol PR exposure in the
current study was 23.9 (7.92) days (range
8.0–43.0 days). The mean (SD) final stable
tapentadol PR dose was 271.1 (113.68) mg/day
(range 100.0–500.0 mg/day).
Global Judgment of Driving Ability
Approximately two-thirds [65.7% (23/35)] of
patients receiving tapentadol PR treatment were
classified as fit to drive based on the global
judgment. Of the 23 patients who were
classified as fit to drive, 7 had adequate driving
ability, 11 had performance deficits that could
be compensated, and 5 had performance
deficits that could be compensated to a limited
extent. The five patients with performance
deficits that could be compensated to a limited
extent were classified as fit to drive because their
relevant scores as defined in a previous study
[10] for each single test (cognitrone,
tachistoskopic traffic conception, and
determination) were C16th percentile.
Twelve (34.3%) patients were classified as
not fit to drive. Of those patients, three had
inadequate driving ability, seven had non-
compensable performance deficits, and two
had performance deficits that could be
compensated to a limited extent. The two
patients with performance deficits that could
be compensated to a limited extent were
classified as not fit to drive because their
scores for C1 single test (cognitrone,
tachistoskopic traffic conception, and/or
determination) were \16th percentile [10].
Overview of Individual Test Results
Individual test results from the Vienna Test
System-Traffic Plus are summarized in Table 2.
More than 70% of patients were classified as
having a successful outcome for the cognitrone,
tachistoskopic traffic conception,
determination, peripheral perception (field of
vision and tracking deviation), Vienna Risk
Taking Test-Traffic, two-hand coordination,
Table 2 Vienna Test System-Trafﬁc Plus individual test





Vienna Risk-Taking Test—Trafﬁc 35 (100)
Tachistoskopic trafﬁc conception test 33 (94.3)
Vigilance—mean value reaction time
correct hits
32 (91.4)
Vigilance—number of correct hits 31 (88.6)
Vigilance—number of incorrect hitsb 30 (85.7)
Determination test 30 (85.7)
Visual pursuit test 29 (82.9)






Two-hand coordination test 25 (71.4)
Reaction test (mean reaction time) 23 (65.7)
Reaction test (mean motor time) 20 (57.1)
Adaptive matrices test 11 (31.4)
a A positive response was deﬁned as a test result C16th
percentile of the normally distributed test data from a
representative age-independent sample
b Fewer incorrect hits is associated with a better score
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vigilance, and visual pursuit tests. Between 50
and 70% of patients had successful reaction
tests (mean reaction time and mean motor
time). A total of 31.4% (11/35) of patients had
a successful adaptive matrices test.
Exploratory Analyses of Variables
Affecting Global Judgment
Exploratory subgroup analyses were conducted
to determine the impact of IQ, educational
level, age, daily dose of tapentadol PR, current
pain intensity, and distance driven in the
previous year on global judgment (Table 3).
Patients with an IQ C 85 generally performed
better in the test system and were more fit to
drive than patients with an IQ\85, but the
differences were not statistically significant
(P = 0.2590, Fisher’s exact test). Patients who
had driven [9,000 km in the previous year
tended to have better global judgment than
those who had driven B9,000 km (P = 0.0577,
Fisher’s exact test). Patients [58 years of age
performed significantly worse and were less fit
to drive than those B58 years of age
(P = 0.0107, Fisher’s exact test). The
following variables had no effect on global
judgment assessments of driving ability:
educational level [B3 (no degree, secondary
school, or vocational training) vs. [3 (higher
school or university degree); P = 0.6399;
Fisher’s exact test], total daily dose of
tapentadol PR ([200 vs. B200 mg/day;
P = 0.4885; Fisher’s exact test), and current
pain intensity [\3 vs. C3 (NRS-3); P = 0.4340,
Fisher’s exact test].
Efficacy-Related Parameter
Pain scores on the 11-point NRS remained
relatively unchanged from the start to the end
of the trial, indicating that the pain relief
achieved during the previous phase 3b studies
[22, 23] was maintained with continued
tapentadol PR treatment during this trial.
Pain intensity scores are summarized in
Table 4.
Table 3 Global judgment ratings by IQ, distance driven in
the previous year, age, education level, TDD of tapentadol
PR, and current pain intensity














TDD of tapentadol PR
B200 mg 12 8




IQ intelligence quotient, PR prolonged release, TDD total
daily dose
a P = 0.0107 vs. patients B58 years of age (in favor of
patients B58 years of age)
b For educational level, a level of B3 indicates no school
degree or secondary school or vocational training
completed, and a level of [3 indicates completion of
higher school or a university degree
c Current pain intensity was rated at the test visit on an
11-point numerical rating scale (0 = ‘‘no pain’’ to
10 = ‘‘pain as bad as you can imagine’’)
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Safety
Non-serious TEAEs were reported by 5.3% (2/38)
of patients. One patient reported
nasopharyngitis and one patient had a
contusion of the rib cage; both of these TEAEs
were considered by the investigator to be
unrelated to study drug. No serious TEAEs,
deaths, or discontinuations due to adverse
events were reported. There were no notable
changes observed in vital signs, except for
increases in blood pressure and pulse rate
during the test visit. During the test visit,
mean (SD) systolic blood pressure was
10.3 (15.50) mmHg higher, diastolic blood
pressure was 11.2 (11.14) mmHg higher, and
pulse rate was 9.4 (18.56) beats per minute
higher compared with the enrollment visit.
These changes were not considered to be
medically relevant.
DISCUSSION
Based on the global judgment, results of this
trial show that patients under treatment with a
stable dose of tapentadol PR (50–250 mg bid) for
the management of non-malignant, chronic
low back pain or osteoarthritis knee pain do
not have clinically significant impairment of
psychomotor or cognitive function that would
prevent them from performing complex daily
activities, such as driving a car. All individual
tests of the Vienna Test System-Traffic Plus
supported the results of the global judgment,
except for the adaptive matrices test.
The driving ability of patients under stable
tapentadol PR treatment in this trial is
comparable to that observed in previous
studies in patients under stable treatment with
transdermal fentanyl [10] or transdermal
buprenorphine [9]. Results of those studies [9,
10] showed that the driving ability of patients
under stable transdermal treatment with
fentanyl or buprenorphine was non-inferior to
that of healthy, untreated subjects, indicating
that patients on stable treatment with strong
opioids might be able to drive safely based on
individual evaluations. The percentage of
patients (34.3%) in the current trial with an
individual result C16th percentile for 5 key tests
(cognitrone, tachistoskopic traffic conception,
determination, vigilance, and two-hand
coordination tests) was comparable to or
higher than the percentage of patients with an
individual result C16th percentile in those
previous studies with transdermal fentanyl
[10] or transdermal buprenorphine [9].
Exploratory subgroup analyses showed that
educational level, the total daily dose of
tapentadol PR, and current pain intensity at








to ﬁnal visit (n5 33)
Mean (SD) 2.7 (1.27) 2.6 (1.63) 2.5 (1.62) -0.2 (1.0)
Median 3.0 3.0 2.0 0.0
Range 0.0 to 6.0 0.0 to 6.0 0.0 to 6.0 -2.0 to 2.0
NRS numerical rating scale, SD standard deviation
a Pain intensity scores at the enrollment and ﬁnal visits were the average pain intensity scores during the last 3 days
(11-point NRS-3); the score at the test visit was current pain intensity (11-point NRS)
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the test visit had no effect on driving ability
assessments. Patients in this study population
were on a stable dose of tapentadol PR and their
pain was well controlled at enrollment, as
indicated by the low mean pain intensity score
(2.7). At these stable doses of tapentadol PR,
pain control was maintained throughout the
study, with mean pain intensity scores of 2.6 at
the test visit and 2.5 at final evaluation. Patients
with a higher IQ (C85) and those who had
driven greater distances in the previous year
([9,000 km) tended to perform better in the test
system and be fit to drive, although these
differences did not reach statistical
significance. A significant difference was
observed in driving ability between older
([58 years of age) and younger patients. These
results are not unexpected, given the previously
demonstrated effect of age on driving ability in
a general population of individuals holding
driving licenses [26]. Previous results have
shown poorer performance for older drivers
(60–82 years of age) compared with middle-
aged drivers (40–50 years) [26] in measures of
driving ability, including performance on a
traffic-related tachistoskopic perception test
and the amount of time needed in tracking
and reaction tests.
There were potential limitations to this study
that should be considered. The global judgment
results should be interpreted with caution due
to the exploratory nature of the analyses. The
use of a historical comparison, rather than
healthy, untreated controls, should also be
considered. Nevertheless, the Vienna Test
System-Traffic Plus has been validated against
a standard driving test and can use a reference
population for internal comparison [21]. In
addition, no pre-study measurements of
driving ability were performed, so a causal
treatment effect on patients with a negative
global judgment (i.e., those that were
considered not fit to drive) could not be
determined; future studies should assess
driving ability before and after tapentadol
treatment initiation. This study, like the
majority of studies evaluating effects of
opioids on cognitive function (including
driving ability), is also limited by the duration
of the study and does not report on long-term
treatment effects [27]. However, unlike other
studies, in the current study patients were on
drug for 12 weeks and on stable treatment for at
least 6 weeks prior to entering the trial as they
had previously participated in another clinical,
well-documented good clinical practice trial
(ClinicalTrials.gov Identifiers: NCT00982280,
NCT00986258, NCT00983073, or
NCT00983385 [22, 23] ).
Analgesic therapy for the management of
non-malignant, chronic pain may not only
provide adequate pain relief, but may also
allow patients to preserve their independence
and stay active, including maintaining the
ability to drive safely [4]. Pain of high
intensity can reduce cognitive capacity and
impair driving performance [28, 29]; when
pain intensity is reduced, patients may be
better able to focus on driving. Consistent
with results of the current study, numerous
studies have shown that patients on stable doses
of opioid analgesics may be able to drive safely
based on individual evaluations [5–10].
Epidemiologic evidence also indicates that
patients on stable doses of opioid analgesics
are not at an increased risk for being in fatal or
non-fatal car accidents [6].
CONCLUSION
Results of this trial based on a global judgment
parameter suggest that most patients under
treatment with a stable dose of tapentadol PR
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(50–250 mg bid) for the management of severe
chronic pain would be able to drive. Outcomes
of the current study are overall consistent with
earlier studies [9, 10], supporting driving ability
for patients under stable treatment with strong
opioids. Methodological limitations (e.g., lack
of pre-study measurement of driving ability)
need to be taken into account when
interpreting these results. Individual responses
to treatment with tapentadol PR may vary, and
individual driving assessments for patients who
are prescribed tapentadol should be considered
in cases of uncertainty for an individual patient
(e.g., patients with additional risk factors, such
as impaired cognitive or psychomotor
performance). In general, the safety profile of
tapentadol PR observed in this study was
consistent with that observed in previous
multiple-dose studies of tapentadol PR in
patients with non-malignant, chronic pain
[20, 22, 23, 30–32].
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